What Will Drug Development Look Like in 2036?
Members of The Medicine Maker’s 2026 Power List predict how AI, new modalities, integrated data, and shifting global markets will reshape the industry
Clinical Scorecard: What Will Drug Development Look Like in 2036?
At a Glance
Category Detail
Condition Drug Development Key Mechanisms Integration of AI, gene editing, and data-driven approaches in drug development. Target Population Patients with various diseases, including rare and common conditions. Care Setting Pharmaceutical and biotechnology industry.
Key Highlights
The boundary between small molecules and biologics will become obsolete. AI will play a crucial role in drug development, from target identification to clinical trial design. Gene therapy approaches will become standard in drug development. Drug development will be more integrated and less fragmented. The geographic center of early-stage drug development is expected to shift to Asia. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with diseases previously considered beyond reach.
Advancements in diagnostics and predictive tools will enhance early assessment of drug efficacy.
Clinical Best Practices
Utilize AI to connect decisions across the entire drug development pathway. Incorporate real-world evidence to predict drug efficacy. Adopt data-driven, adaptive approaches to drug development. Related Resources & Content
